Great Debates in WM
Moderated by Carl Harrington- IWMF President
Rituxan Maintenance vs. No Maintenance
Morton Coleman MD – Weill Cornell Medical College vs. Stephen Ansell MD, PhD – Mayo Clinic, 2019 Ed Forum
Limited Treatment Duration vs. Continuous Pill
Edward Stadtmauer, MD – University of Pennsylvania vs. Jorge Castillo, MD – Dana Farber Cancer Institute, 2019 Ed Forum
The experts debate hot topics in long term treatment decisions for WM
Immunotherapy – Making the Immune System Target WM Cells
Stephen Ansell MD, PhD, Mayo Clinic, Rochester, 2019 Ed Forum
Explains how immunotherapy activates T-cells into killer T-cells and prevents them from being switched off, so that the T-cell has increased ability to target cancer cells. Over time, T-cells can become “exhausted” and switched off with loss of function. Strategies to block these “switched off” signals with PD1 blockade and CTLA-4 blockade are presented. T-cells in WM are not activated, strategies are presented to activate the T-cell by “waking’ them up by giving them a “poke.” T-cells in WM also do not “lock on” to their targets. Chimeric antigen receptor (CAR) T-cell therapy may give the T-cell a new way to “dock” onto WM cells.
The Research Roadmap Roundup
Stephen Ansell MD, PhD - Mayo Clinic Rochester, 2018 Ed Forum
Provides the IWMF-LLS Strategic Research Roadmap and addresses the uniqueness of WM, its genomics, epigenomics, MYD88 L265P and CXCR4 mutations, and treatment options
Overview of the IWMF-LLS Strategic Research Roadmap – Our Track for the Future
Provides the IWMF-LLS Strategic Research Roadmap and addresses the uniqueness of WM, its genomics, epigenomics, MYD88 L265P and CXCR4 mutations, treatment options, and survival
An Exciting Time in Waldenstrom's!
Stephen M. Ansell MD, PhD – Mayo Clinic, Rochester, 2016 Ed Forum
Explains the IWMF-LLS Strategic Research Roadmap and its importance to the WM community
No slides available
IWMF Research Roadmap Overview & Bone Marrow Tumor Microenvironment
Stephen Ansell, MD, PhD - Mayo Clinic, Rochester, 2016 Ed Forum
Covers what is unique about WM, as well as, genomics, epigenomics, MYD88 L265P and CXCR4 mutations, survival, and treatment options
Research and IWMF
Stephen M. Ansell MD, PhD – Mayo Clinic, Rochester, 2015 Ed Forum
Dr. Ansell talks about his interest in WM, the funding provided by the IWMF for his research, and the team effort he is involved in with WM patients and the IWMF. He also discusses the current exciting times for WM in terms of research, with opportunities for improved treatments and the possibility of a cure in the near future.
No slides available
How B-cells Work and Talk to Each Other
Reviews how lymphocytes become plasma cells and then produce antibodies and activate the B-cell receptor pathway, the Toll-like receptor pathway, causes of increased production of IgM in WM, cytokines, chemokines, receptor/ligand interactions and cell communications
Pulling the Plug on Cancer Cell Communication
Stephen Ansell, MD, PhD – Mayo Clinic, Rochester, 2014 Ed Forum Covers why WM cells need to communicate and how they communicate, cytokine networks, B-cell receptor pathway, Toll-like receptor pathway, what goes wrong in WM, what causes the increased production of IgM in WM, B-lymphocyte stimulator (BLyS) increase in WM, and why we need to stop the communication
No video available
Strategic Research Roadmap: Getting to a World Without WM
Strategic Research Roadmap: Getting to a World Without WM - Dr. Ansell, who also is a Board member of the IWMF, presented details about the IWMF/LLS Strategic Research Roadmap and the exciting discoveries with regard to WM that are taking place due to the Roadmap research efforts, and encouraged everyone to participate and be engaged with what the IWMF is doing on their behalf.
Stephen M. Ansell, MD, PhD, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Minnesota. Dr. Ansell currently serves as chair of the Mayo Clinic Lymphoma Disease-Oriented Group and chair of faculty development and recruitment for the Division of Hematology. He joined the staff of Mayo Clinic in 1999 and holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine and Science.